203258-44-0

Basic information

• Product Name: 2-(2-AMINOETHYL)-1 3-DI-BOC-GUANIDINE
• Synonyms: Propanoylchloride,4-methoxy-;2-(2-Aminoethyl)-1,3-di-Boc-guanidine technical, >=90% (HPLC);Carbamicacid,N,N'-[(2-aminoethyl)carbonimidoyl]bis-,bis(1,1-dimethylethyl)ester;Carbamic acid, N,N'-[(2-aminoethyl)carbonimidoyl]bis-, C,C'-bis(1,1-dimethylethyl) ester;tert-butyl [N'-(2-aminoethyl)-N-(tert-butoxycarbonyl)carbamimidoyl]carbamate (non-preferred name)
• CAS NO: 203258-44-0
• Molecular Formula: C₁₃H₂₆N₄O₄
• Molecular Weight: 302.37
• Mol File: 203258-44-0.mol

Chemical Properties

• Melting Point: 95-98 °C
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• Storage Temp.: −20°C
• PKA: 7.01±0.46(Predicted)
• CAS DataBase Reference: 2-(2-AMINOETHYL)-1 3-DI-BOC-GUANIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-AMINOETHYL)-1 3-DI-BOC-GUANIDINE(203258-44-0)
• EPA Substance Registry System: 2-(2-AMINOETHYL)-1 3-DI-BOC-GUANIDINE(203258-44-0)

Safety Data

• WGK Germany: 3
• F: 10-34
• Hazardous Substances Data: 203258-44-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
2-(2-AMINOETHYL)-1,3-DI-BOC-GUANIDINE is used as a reagent for various synthetic transformations, particularly in the preparation of biologically active molecules and pharmaceuticals. Its guanidine moiety and BOC protecting groups facilitate the synthesis process, making it a valuable component in the creation of complex organic compounds.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-(2-AMINOETHYL)-1,3-DI-BOC-GUANIDINE is used for its potential interactions with biological targets. The presence of the aminoethyl group allows for the exploration of its binding and activity with various biological systems, which can lead to the development of new therapeutic agents and drug candidates.
Used in the Synthesis of Guanidine-Containing Compounds and Polymers:
Due to its basic properties and the presence of the guanidine functional group, 2-(2-AMINOETHYL)-1,3-DI-BOC-GUANIDINE is utilized in the synthesis of guanidine-containing compounds and polymers. This application is crucial for the development of new materials with specific properties, such as those used in drug delivery systems or as active pharmaceutical ingredients.

Upstream product

• 107-15-3 ethylenediamine 
• 322474-21-5 N,N'-bis-Boc-S-methyl-isothiourea 
• 145013-05-4 tert-butyl N-({[(tert-butoxy)carbonyl]amino}methanethioyl)carbamate 
• 152120-54-2 N,N'-bis( tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine 
• 207857-15-6 1,3-di(tert-butyloxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine 

Downstream Products

• 1610839-77-4 tert-butyl-1-((4R)-2-(4-methoxyphenyl)-5,5-dimethyl-1,3-dioxan-4-yl)-10,10-dimethyl-1,8-dioxo-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate 
• 1620785-96-7 (4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)phenyl)(2-iminoimidazolidin-1-yl)methanone 

Relevant articles and documents

Modification of Biphenolic Anti-Bacterial to Achieve Broad-Spectrum Activity

The Gram-positive bacteria, methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative bacteria, Acinetobacter baumannii, are pathogens responsible for millions of nosocomial infections worldwide. Due to the threat of bacteria evolving resistance to antibiotics, scientists are constantly looking for new classes of compounds to treat infectious diseases. The biphenolic analogs of honokiol that were most potent against oral bacteria had similar bioactivity against MRSA. However, all the compounds proved ineffective against A. baumannii. The inability to inhibit A. baumannii is due to the difficult-to-penetrate lipopolysaccharide-coated outer membrane that makes it challenging for antibiotics to enter Gram-negative bacteria. The C 2 scaffold was optimized from the inhibition of Gram-positive bacteria to broad-spectrum antibacterial compounds that inhibit the dangerous Gram-negative pathogen A. baumannii.

EIF4E INHIBITORS AND USES THEREOF

The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

The synthesis and glycosidase inhibitory activity of analogues of tiruchanduramine

Five analogues (7a-e) of the metabolite tiruchanduramine 1 were prepared. Compounds 7d and 7e were specific inhibitors of yeast α-glucosidase, whilst 7e specifically inhibited Bacillus α-glucosidase. Compounds 7b and 7c were the best inhibitors of β-gluco

Virtual screening guided design, synthesis and bioactivity study of benzisoselenazolones (BISAs) on inhibition of c-met and its downstream signalling pathways

c-Met is a transmembrane receptor tyrosine kinase and an important therapeutic target for anticancer drugs. In this study, we designed a small library containing 300 BISAs molecules that consisted of carbohydrates, amino acids, isothiourea, tetramethylthiourea, guanidine and heterocyclic groups and screened c-Met targeting compounds using docking and MM/GBSA. Guided by virtual screening, we synthesised a series of novel compounds and their activity on inhibition of the autophosphorylation of c-Met and its downstream signalling pathway proteins were evaluated. We found a panel of benzisoselenazolones (BISAs) obtained by introducing isothiourea, tetramethylthiourea and heterocyclic groups into the C-ring of Ebselen, including 7a, 7b, 8a, 8b and 12c (with IC50 values of less than 20 μMin MET gene amplified lung cancer cell line EBC-1), exhibited more potent antitumour activity than Ebselen by cell growth assay combined with in vitro biochemical assays. In addition, we also tested the antitumour activity of three cancer cell lines without MET gene amplification/activation, including DLD1, MDA-MB-231 and A549. The neuroblastoma SK-N-SH cells with HGF overexpression which activates MET signalling are sensitive to MET inhibitors. The results reveal that our compounds may be nonspecific multitarget kinase inhibitors, just like type-II small molecule inhibitors. Western blot analysis showed that these inhibitors inhibited autophosphorylation of c-MET, and its downstream signalling pathways, such as PI3K/AKT and MARK/ERK. Results suggest that bensoisoselenones can be used as a scaffold for the design of c-Met inhibiting drug leads, and this study opens up new possibilities for future antitumour drug design.

Dimeric indole alkaloid compounds, preparation method thereof and use thereof in preparation of antibacterial drugs

The present invention belongs to the fields of organic synthesis and pharmaceutical chemistry. In particular, the present invention relates to a series of dimeric indole alkaloid compounds as shown instructural general formula I, a preparation method thereof and use thereof in preparation of antibacterial drugs. After in vitro activity screening, results show that the compounds have strong antibacterial activity, in particular have specific inhibitory effects on strains of gram-positive bacteria such as staphylococcus, bacillus and enterococcus, and related drug-resistant strains thereof, andcan be used as lead compounds for developing new antibacterial drugs.

Norbornane-based cationic antimicrobial peptidomimetics targeting the bacterial membrane

The design, synthesis and evaluation of a small series of potent amphiphilic norbornane antibacterial agents has been performed (compound 10 MIC = 0.25 μg/mL against MRSA). Molecular modelling indicates rapid aggregation of this class of antibacterial agent prior to membrane association and insertion. Two fluorescent analogues (compound 29 with 4-amino-naphthalimide and 34 with 4-nitrobenz-2-oxa-1,3-diazole fluorophores) with good activity (MIC = 0.5 μg/mL against MRSA) were also constructed and confocal microscopy studies indicate that the primary site of interaction for this family of compounds is the bacterial membrane.

Design and synthesis of short amphiphilic cationic peptidomimetics based on biphenyl backbone as antibacterial agents

Antimicrobial peptides (AMPs) and their synthetic mimics have received recent interest as new alternatives to traditional antibiotics in attempts to overcome the rise of antibiotic resistance in many microbes. AMPs are part of the natural defenses of most living organisms and they also have a unique mechanism of action against bacteria. Herein, a new series of short amphiphilic cationic peptidomimetics were synthesized by incorporating the 3′-amino-[1,1′-biphenyl]-3-carboxylic acid backbone to mimic the essential properties of natural AMPs. By altering hydrophobicity and charge, we identified the most potent analogue 25g that was active against both Gram-positive Staphylococcus aureus (MIC = 15.6 μM) and Gram-negative Escherichia coli (MIC = 7.8 μM) bacteria. Cytoplasmic permeability assay results revealed that 25g acts primarily by depolarization of lipids in cytoplasmic membranes. The active compounds were also investigated for their cytotoxicity to human cells, lysis of lipid bilayers using tethered bilayer lipid membranes (tBLMs) and their activity against established biofilms of S. aureus and E. coli.

Synthesis and evaluation of cationic norbornanes as peptidomimetic antibacterial agents

A series of structurally amphiphilic biscationic norbornanes have been synthesised as rigidified, low molecular weight peptidomimetics of cationic antimicrobial peptides. A variety of charged hydrophilic functionalities were attached to the norbornane scaffold including aminium, guanidinium, imidazolium and pyridinium moieties. Additionally, a range of hydrophobic groups of differing sizes were incorporated through an acetal linkage. The compounds were evaluated for antibacterial activity against both Gram-negative and Gram-positive bacteria. Activity was observed across the series; the most potent of which exhibited an MIC's ≤ 1 μg mL-1 against Streptococcus pneumoniae, Enterococcus faecalis and several strains of Staphylococcus aureus, including multi-resistant methicillin resistant (mMRSA), glycopeptide-intermediate (GISA) and vancomycin-intermediate (VISA) S. aureus.

Exploring structural motifs necessary for substrate binding in the active site of Escherichia coli pantothenate kinase

The coenzyme A (CoA) biosynthetic enzymes have been used to produce various CoA analogues, including mechanistic probes of CoA-dependent enzymes such as those involved in fatty acid biosynthesis. These enzymes are also important for the activation of the pantothenamide class of antibacterial agents, and of a recently reported family of antibiotic resistance inhibitors. Herein we report a study on the selectivity of pantothenate kinase, the first and rate limiting step of CoA biosynthesis. A robust synthetic route was developed to allow rapid access to a small library of pantothenate analogs diversified at the β-alanine moiety, the carboxylate or the geminal dimethyl group. All derivatives were tested as substrates of Escherichia coli pantothenate kinase (EcPanK). Four derivatives, all N-aromatic pantothenamides, proved to be equivalent to the benchmark N-pentylpantothenamide (N5-pan) as substrates of EcPanK, while two others, also with N-aromatic groups, were some of the best substrates reported for this enzyme. This collection of data provides insight for the future design of PanK substrates in the production of useful CoA analogues.

An optimised synthesis of 2-[2,3-Bis(tert -butoxycarbonyl)guanidino] ethylamine

This short report describes an improved, reliable, and high-yielding (>90%) synthesis of 2-[2,3-bis(tert-butoxycarbonyl)guanidino]ethylamine. The method is scalable (>5 g), and the product obtained directly from the reaction mixture requires no further purification. In addition, this methodology can be successfully applied to other diamine substrates (1,3-propyl and 1,4-butyl; 70% and 61% yield, respectively).